Lenvatinib (E7080) is an oral multikinase inhibitor that targets VEGFR1‐3, FGFR1‐4, RET, c‐kit and PDGFRa, obtained considerable success in clinical trials of different cancer types, including NSCLC, thyroid cancer, gastric cancer, HCC, RCC and endometrial cancer.134, 157, 158, 159, 160, 161. The gene discussed is FGFR1; the disease is thyroid gland carcinoma.